Ypsomed’s self-injection device track record

In January 2026, YpsoLoop takes the top prize in the Patient-Centric Design category at the Pharmapack Awards in Paris, recognizing its focus on safe and intuitive self-injection. Features such as ClickGuide technology and ergonomic design aim to support user confidence and reduce user errors. This milestone highlights YpsoLoop’s approach to combining patient-centric design with sustainability.

See why Ypsomed won the award

In early 2026, Ypsomed introduces Clear to Clinic, enabling early clinical use of YpsoMate 1 mL and YpsoMate 2.25 mL with clinic-ready devices. Rapid access to assembled systems and submission-ready documentation supports faster study start and flexible trial design. This milestone introduces a new way to deploy autoinjectors in clinical trials, with ready-to-use devices and coordinated supply reducing delays and complexity.

See how Clear to Clinic works

In its Innovation Hub, Ypsomed introduces a circularity initiative exploring how eco-designed device platforms can be combined with take-back and recycling pathways. The work focuses on designing for disassembly, reducing material complexity, and collaborating with partners across the value chain to understand real-world collection and recovery. As an ongoing innovation project, it reflects Ypsomed’s commitment to developing practical, scalable approaches to circularity and advancing more sustainable self-injection solutions.

Explore Ypsomed’s circularity approach

Just a week after its official reveal, YpsoLoop wins top honors in the Drug Device and Innovation category at the 2025 CPHI Pharma Awards in Frankfurt. This award recognizes groundbreaking achievements that advance patient care in drug delivery. This recognition highlights Ypsomed’s position at the forefront of drug delivery innovation, and acknowledges the collaboration and dedication of Ypsomed’s cross-functional teams whose collective expertise and hard work brought YpsoLoop from concept to reality. Ypsomed remains committed to working with partners across the industry to advance sustainable, patient-centered solutions that make a lasting impact.

See why YpsoLoop won the CPHI award

In October, Ypsomed reveals YpsoDot, a pre-filled, cartridge-based pull-push pen designed for multiple injections of a fixed dose. The pen is designed to support the growing needs in obesity management and related therapies. 
 
With a strong focus on patient needs and ongoing advancements in obesity and metabolic therapies, YpsoDot is an economic and environmentally friendly pen built to accommodate the next generation of medications – supporting better health outcomes through simple and intuitive delivery technology. 

Explore the YpsoDot platform

On October 21 at PDA in Vienna, Ypsomed reveals YpsoLoop, the first autoinjector platform designed for circularity. The two new 1 mL and 2 mL platform versions enable material recovery through a design enabling automated disassembly and efficient recycling, while offering the convenience of a pre-filled, two-step autoinjector. A paradigm-shifting circular solution, YpsoLoop integrates into existing production environments, supporting a transition toward more sustainable drug delivery solutions.

Explore the YpsoLoop platform

In October 2025, Ypsomed reveals a reusable mechanical autoinjector concept in its Innovation Hub, designed for long-term use and reduced environmental impact. The platform combines intuitive handling with a simple cartridge loading mechanism and reliable push-on-skin activation. With durable components and minimized disposable parts, it supports both sustainability and optimized cost of goods. This milestone highlights Ypsomed’s focus on reusable solutions that address growing demand for cost-efficient, user-friendly, and environmentally responsible self-injection devices.

Explore the reusable autoinjector concept

Ypsomed reveals CliniPilot, an innovative add-on technology available for YpsoMate 1 mL and YpsoMate 2.25 mL autoinjectors, transforming them into smart, connected devices, enabling connected clinical trials. CliniPilot automatically captures and transmits key injection data, and supports pre-approval trials and post-approval RWE programs across traditional, hybrid, and fully decentralized models.

This milestone highlights Ypsomed’s role in advancing smarter, more connected clinical trials and setting the foundation for future data-driven solutions.

See how CliniPilot supports connected trials

In September 2025, the U.S. Food and Drug Administration (FDA) grants 510(k) clearance for SmartPilot, a digital connectivity add-on developed by Ypsomed. The device transforms the YpsoMate 1 mL autoinjector into a connected system that automatically captures and transmits injection data.

The clearance marks an important step toward digital health solutions that offer deeper insights into therapy use, enable objective monitoring, and support improved adherence and treatment outcomes.

Explore the FDA-cleared SmartPilot solution

In June 2025, Ypsomed officially opens its first production facility in Changzhou, China, marking a significant step in its global growth strategy. Located in a high-tech industrial park near Shanghai, the 15,000 m² site was completed in just 14 months and will produce up to 100 million injection devices annually for the Chinese market. The facility enables faster, more sustainable delivery of self-injection systems in Asia and reflects Ypsomed’s long-term commitment to the region. Built to LEED Platinum standards and certified under ISO 13485, the site meets the highest environmental and quality benchmarks. This strategic investment complements Ypsomed’s broader manufacturing network, including expansion projects in Europe and North America, and underscores its goal of being closer to customers worldwide.

Read about the new China facility

At CPHI China in June 2025, Ypsomed reveals YpsoFlow, a new spring-driven pen platform for GLP-1 and peptide therapies. Designed to deliver up to 0.80 mL with low injection force, an audible end-of-dose click, and a compact, user-friendly form, YpsoFlow enhances patient comfort and confidence. The device is built using only two bio-based plastics and follows eco-design principles, helping pharma partners meet sustainability targets without compromising performance. With broad customization options and regulatory support – including Human Factors and interchangeability studies – YpsoFlow strengthens Ypsomed’s platform strategy for self-injection solutions.

Explore the YpsoFlow platform

Ypsomed expands its NetZero Program to include UnoPen, one of its most widely used and versatile self-injection pen platforms. Now available with ISCC PLUS-certified materials and a certified mass balance approach, UnoPen offers pharma partners a more sustainable option for delivering a wide range of therapies – from insulin to fertility, GLP-1, and growth hormone treatments.

The move reflects Ypsomed’s commitment to decarbonizing across all major platform families, supporting environmental goals without sacrificing regulatory readiness, performance, or patient experience. With this launch, Ypsomed continues to set new industry standards for environmentally responsible device manufacturing, empowering partners to offer eco-conscious combination products at global scale.

Explore the sustainable UnoPen platform

At the 2025 CPHI China Pharma Awards, YpsoDose is honored with the Gold Award in the Drug Delivery Innovation category, acknowledging its leadership in large-volume self-injection. The pre-filled, ready-to-use patch injector impressed the international jury with its technological sophistication, patient-centered design, and high manufacturing quality. YpsoDose enables automated subcutaneous delivery of up to 10 mL, offering new possibilities for chronic condition therapies that were traditionally IV-based. The award underscores Ypsomed’s ability to push the boundaries of platform development and reaffirms its role as a trusted innovation partner for pharma companies navigating the shift to self-administered care.

Explore the award-winning YpsoDose platform

Ypsomed’s YpsoMate 1 mL platform enables the launch of a novel therapy for familial chylomicronemia syndrome (FCS) in the United States. As a rare and serious genetic disorder requiring precise, patient-friendly treatment options, FCS marks a significant new therapeutic area for the platform.

This launch highlights YpsoMate’s 1 mL versatility, meeting the demanding needs of both low-volume specialty indications and large-scale treatments. For pharmaceutical partners, the platform ensures rapid time-to-market, regulatory confidence, and a patient-preferred device format. By powering access to a therapy for an underserved condition, Ypsomed demonstrates its commitment to platform adaptability, operational excellence, and supporting self-care in complex disease areas.

Explore the versatile YpsoMate 1 mL platform

In October 2024, Ypsomed opensa new production hall at itssite inSchwerin, Germany,adding 3,400 m²of manufacturing space, 30 injection‑moldingmachines, and three assembly lines. This investment, supported by CHF 22 million funding,immediatelyincreased capacity by anadditional100 million pens and autoinjectors per year. Building on that momentum, in January 2025 Ypsomed launches“Schwerin II”, a major multi-phase expansion that will add 37,000 m²of production area, automated warehousing, and technical facilities over two years. The total investment–over CHF 500 million–will raise annual capacity by 400–500 million devices.

The project emphasizes eco‑responsible design (LEED Gold standard, solar panels, planned wind energy, CO₂‑neutral buildings) and will create hundreds of new jobs and apprenticeships.Together, these investments significantly enhanceYpsomed’sEuropean manufacturing footprint, strengthen supply‑chain resilience, and support its ability to meet global demand with high‑quality, Swiss‑engineered self-injection solutions.

Read about the Schwerin expansion

Ypsomed introduces a significant enhancement to its YpsoMate 1 mL and YpsoMate 2.25 mL autoinjectors: a new configuration compatible with 8 mm needles. Developed in collaboration with BD (Becton, Dickinson and Company), a global leader in medical technology, the thinner-walled, shorter needle reduces injection force and duration – improving patient comfort and addressing needle-related anxiety.

This technical advancement enhances the injection of high-viscosity formulations while maintaining Ypsomed’s high safety and usability standards. It also offers pharmaceutical partners expanded flexibility to tailor delivery systems to diverse drug characteristics and user needs. The partnership with BD further reinforces Ypsomed’s strategic focus on enabling the next generation of self-injection therapies. By evolving its core platform through smart collaborations, Ypsomed continues to lead in versatile, patient-centered drug delivery.

Explore the enhanced YpsoMate platform

Following the successful commercial launch of the NetZero version of YpsoMate 1 mL in 2023, Ypsomed introduces the YpsoMate 2.25 mL variant as part of its NetZero. Designed for high-volume and often high-viscosity biologics, the YpsoMate 2.25 mL is now available using ISCC PLUS-certified renewable materials, with emissions tracked and reduced using a mass-balance approach.

By extending the program to include this larger-volume device, Ypsomed demonstrates the scalability of its sustainability strategy – without compromising usability, safety, or performance. As part of a growing portfolio of low-carbon self-injection systems, the NetZero version of YpsoMate 2.25 mL reinforces Ypsomed’s position as a leader in sustainable innovation, enabling pharma partners to meet their ESG targets and support patients with more responsible drug delivery solutions.

Explore the sustainable YpsoMate 2.25 mL platform

2024 marks one of the most launch-intensive years in Ypsomed’s history, with the YpsoMate 1 mL and YpsoMate 2.25 mL platforms enabling combination product rollouts across a wide range of indications. Highlights include the launch of methotrexate autoinjectors worldwide – and additional launches in inflammatory bowel disease, asthma, and amyloidosis.

These product introductions across North America, Europe, and Asia underscore Ypsomed’s ability to scale production and support global customers at pace. The year's activity reinforces YpsoMate’s role as a proven, trusted platform and Ypsomed’s position as a strategic partner for delivering high-quality self-injection devices across increasingly complex therapies.

Ypsomed’s ServoPen and YpsoPen become CE-certified under the EU Medical Device Regulation (MDR), unlocking a faster path to market for partners. Thanks to Ypsomed’s platform strategy, each new product variant using these pens can now bypass individual Notified Body reviews prior to market launch, accelerating time-to-market by up to 18 months. By acting as the legal manufacturer and managing the full regulatory scope – from technical documentation to labeling and lifecycle updates – Ypsomed provides a turnkey solution for pharmaceutical companies.

This milestone not only reflects operational excellence and regulatory leadership, but also strengthens Ypsomed’s value proposition as a trusted partner capable of simplifying compliance while enabling rapid commercialization of injectable therapies.

Ypsomed signs a long-term supply agreement with Novo Nordisk for large-scale deliveries of its YpsoMate 1 mL autoinjector. The devices will support self-treatment across multiple metabolic conditions, including GLP-1, reinforcing Ypsomed’s role as a trusted partner in high-demand, global therapy areas. To meet growing demand, Ypsomed commits to a significant expansion of its production capacity by 2030, marking one of the most substantial industrial scale-ups in the company's history.

This strategic contract is described by CEO Simon Michel as a milestone for the company and is widely recognized as such by the financial markets. The agreement underscores Ypsomed’s leadership in platform-based autoinjectors and its ability to deliver industrial excellence at scale – aligning with its long-term commitment to enable broader access to self-care solutions worldwide.

Read about the Novo Nordisk agreement

Ypsomed is awarded the Silver Medal by the independent sustainability rating agency EcoVadis, placing the company among the top 25% worldwide in the “Manufacture of medical and dental instruments and accessories” category. The recognition highlights Ypsomed’s robust performance in environmental protection – particularly its NetZero Program – as well as its strong efforts in labor and human rights, ethics, and sustainable procurement. This award underscores Ypsomed’s commitment to transparent, responsible, and forward-looking business practices across its global operations.

Explore Ypsomed’s sustainability commitment

The Science Based Targets initiative (SBTi) officially validates Ypsomed’s greenhouse gas reduction targets. This validation marks a major step in Ypsomed’s sustainability journey, confirming that its climate goals align with the latest climate science and the objectives of the Paris Agreement. The SBTi endorsement demonstrates Ypsomed’s commitment to achieving measurable, transparent, and science-based emissions reductions across its entire value chain. It reinforces the company’s role as a responsible healthcare partner, integrating climate action into its core strategy and long-term operations.

Ypsomed achieves a major sustainability milestone with the first customer delivery of an YpsoMate 1 mL variant produced under its NetZero Program. Manufactured using renewable ISCC PLUS-certified materials, the devices maintain the same safety, performance, and usability standards trusted by global pharma – now with lower lifecycle emissions. This delivery confirms pharma’s confidence in Ypsomed’s sustainable product roadmap. The NetZero portfolio is expanding and advancing Ypsomed’s role as a leader in climate-conscious drug delivery.

Explore Ypsomed’s NetZero Program

Ypsomed holds the groundbreaking ceremony for its first production facility in China, strategically located in the Changzhou National Hi-tech District. This milestone marks a major step in strengthening Ypsomed’s global manufacturing network and deepening its presence in Asia – a key growth market for self-injection systems. The new site reflects Ypsomed’s commitment to operational excellence, local production close to customer markets, and agile supply capabilities to meet growing regional demand.

Read about the new China facility

Ypsomed’s production facilities in Switzerland and Germany are awarded ISO 14001 certification, demonstrating compliance with internationally recognized environmental management standards. This milestone reflects Ypsomed’s structured, proactive approach to minimizing environmental impact, optimizing resource efficiency, and continually improving sustainability performance. The certification reinforces Ypsomed’s commitment to responsible manufacturing and aligns with its broader NetZero ambitions and ESG objectives across the value chain.

In 2023, Ypsomed celebrates the opening of its upgraded production facility at Lochbachstrasse 26 in Burgdorf, marking a significant step in scaling its manufacturing infrastructure. The modernized and expanded site enhances production capacity, efficiency, and sustainability – reinforcing Ypsomed’s commitment to high-quality, Swiss-engineered delivery systems. This investment underscores the company's long-term industrial strategy and strengthens its ability to reliably supply global markets with advanced injection and infusion solutions.

YpsoMate 1 mL autoinjectors power an unprecedented number of global launches, further solidifying its position as the industry’s most scalable platform for YpsoMate 1 mL and YpsoMate 2.25 mL prefilled syringe autoinjectors. Combination products using YpsoMate 1 mL enter the market across the US, EU, Asia, and other key regions for therapies in oncology, respiratory diseases, autoimmune conditions, and hypercholesterolemia.

This surge demonstrates YpsoMate’s unmatched readiness for commercial deployment across originator and biosimilar products, and its adaptability to different drug profiles and regulatory requirements. By enabling partners to streamline global launches with one device platform, Ypsomed continues to deliver on operational excellence, platform scalability, and global market access.

Ypsomed reinforces its leadership in hormone and metabolic care with a series of strategic UnoPen launches. The platform continues to support insulin therapies in China and Russia, expands fertility treatment access in Europe, and enables a new osteoporosis launch in China. Notably, 2023 also marks UnoPen’s first use in delivering a therapy for hyperparathyroidism across the EU and US – demonstrating the platform’s versatility in meeting the demands of emerging peptide-based treatments. These milestones reflect Ypsomed’s ability to sustain deep therapeutic experience while continuously advancing its reach and clinical relevance across key markets.

Explore the versatile UnoPen platform

Ypsomed enters a strategic partnership with S3 Connected Health to strengthen its digital health ecosystem. The collaboration focuses on delivering customizable, therapy-specific digital solutions that biopharma partners can deploy alongside drug-device combination products. By integrating connected self-injection systems with S3’s digital platforms, Ypsomed enables comprehensive therapy management, patient engagement, and real-world data collection. This initiative supports improved treatment adherence and outcomes, while reinforcing Ypsomed’s role as a digital enabler and trusted partner in next-generation drug delivery.

Read about the S3 Connected Health partnership

Ypsomed’s YpsoMate 2.25 mL Pro autoinjector makes its commercial debut in 2023 with the launch of a therapy for atopic dermatitis, first across the EU, UK and Canada, and then in the US and Japan. This first market entry marks a major validation for the high-force platform, specifically engineered for the subcutaneous delivery of viscous biologics at larger volumes – up to 2.25 mL. With its constant-force spring mechanism and proven usability features, YpsoMate 2.25 mL Pro expands the boundaries of what can be self-injected, enabling pharma and biotech companies to bring complex monoclonal antibodies and other next-gen formulations to patients in a simple, ready-to-use device.

This launch underscores Ypsomed’s leadership in platform development, and its commitment to supporting partners with robust, scalable, and user-centered delivery systems for even the most challenging drug profiles.

Explore the YpsoMate 2.25 mL platform

Ypsomed partners with Sidekick Health, a leader in digital therapeutics, to integrate a dedicated self-injection module into Sidekick’s behavioral intervention platform. This collaboration is designed to support patients managing chronic conditions such as cancer, autoimmune, or metabolic diseases by offering personalized guidance, motivation, and real-time feedback throughout the injection process. By combining Ypsomed’s device expertise with Sidekick’s digital engagement capabilities, the partnership aims to improve adherence, empower patients, and enhance therapy outcomes – reinforcing Ypsomed’s commitment to digital health innovation and holistic self-care ecosystems.

Read about the Sidekick Health partnership

With the launch of YpsoMate 5.5 mL, Ypsomed becomes one of the first companies to offer a pre-filled, single-use autoinjector capable of safely and effectively delivering volumes up to 5.5 mL. This innovation marks a pivotal shift in self-injection capabilities – making it possible to transition complex biologics, previously limited to intravenous infusions, into patient-friendly, at-home treatments. For pharmaceutical companies, YpsoMate 5.5 mL unlocks new opportunities to repurpose and differentiate high-value therapies. For patients, it represents greater autonomy and comfort in managing chronic conditions.

As part of Ypsomed’s expanding platform portfolio, this milestone underscores the company’s leadership in pushing the boundaries of usability and volume – meeting the demands of next-generation biologics and reinforcing its strategic importance in the drug delivery ecosystem.

See how YpsoMate 5.5 mL enables large-volume delivery

Between 2021 and 2022, YpsoMate 1 mL and YpsoMate 2.25 mL continue to expand their therapeutic footprint with successful global launches in autoimmune diseases. This period marks the platform’s first entry into dermatological care through multiple launches of a therapy for plaque psoriasis – an autoimmune skin condition affecting millions worldwide. These achievements highlight YpsoMate’s platform flexibility across indications and its growing relevance for pharmaceutical partners advancing treatments in both systemic and specialty care.

Ypsomed’s SmartPilot for UnoPen is honored with the prestigious Red Dot Award, one of the most renowned distinctions for product design and innovation. The award recognized its outstanding user-centric design, intuitive interface, and ability to transform a traditional injection pen into a connected, smart therapy companion. By enabling real-time guidance, adherence tracking, and injection data capture, SmartPilot enhances patient confidence. This recognition reinforces Ypsomed’s leadership in combining usability, technology, and digital health, and marks a key milestone in the evolution of smart self-injection solutions.

See why SmartPilot won the Red Dot Award

Ypsomed becomes a founding member of the Alliance to Zero, a non-profit association dedicated to supporting the pharmaceutical and biotech industries in their transition to net-zero greenhouse gas emissions. As one of the early contributors to this initiative, Ypsomed commits to shaping shared standards, fostering innovation, and promoting sustainable practices across the value chain. This collaboration underscores Ypsomed’s belief that sustainability must be pursued collectively – through cross-sector dialogue, transparency, and actionable roadmaps. The move further reinforces Ypsomed’s leadership in driving environmental responsibility within drug delivery and healthcare manufacturing.

Read about the Alliance to Zero initiative

Ypsomed continues to grow its global presence and therapeutic impact. UnoPen is launched for insulin in Brazil, expanding access to essential diabetes care in one of Latin America’s most important healthcare markets. At the same time, a growth hormone therapy becomes the first of its kind to be launched in a UnoPen – marking the platform’s entry into a new indication across high-value regions including Europe and Japan. These launches reflect Ypsomed’s ability to support complex biologics and hormone therapies on a global scale.

Explore the UnoPen platform

Ypsomed signs a declaration of intent with the Science Based Targets initiative (SBTi), committing to align its climate goals with the latest scientific consensus for limiting global warming. This step formalizes Ypsomed’s dedication to a science-based pathway for reducing greenhouse gas emissions across its value chain. By engaging with the SBTi, Ypsomed strengthens the credibility of its environmental roadmap and takes a meaningful step toward measurable climate action.

YpsoMate On becomes the world’s first autoinjector with built-in connectivity for prefilled syringes, marking a major step toward seamless integration of drug delivery and digital health ecosystems. By embedding connectivity directly into the device without altering its proven two-step usability, Ypsomed empowers pharma partners to enable real-time adherence monitoring, therapy personalization, and improved patient outcomes. This launch reinforces Ypsomed’s position at the forefront of connected self-injection technology.

Ypsomed formally integrates sustainability into its corporate strategy, marking a decisive step toward more responsible and future-oriented business practices. This shift introduces a holistic approach, embedding environmental and social responsibility into all business units and activities – from product design and manufacturing to supply chain and corporate governance. This milestone reaffirms Ypsomed’s commitment to long-term value creation for patients, partners, and society.

Explore Ypsomed’s sustainability strategy

YpsoMate Zero becomes the world’s first certified zero-carbon-emission autoinjector, setting a new industry benchmark for sustainable drug delivery. Built on the trusted YpsoMate platform, it combines proven usability and reliability with a fully carbon-neutral production process – achieved through material choices, optimized manufacturing, and verified offsetting. As environmental concerns rise across healthcare, this innovation reaffirms Ypsomed’s role as a pioneer in eco-conscious medical technology.

Explore the sustainable YpsoMate platform

Following its initial launch in Japan, FixPen continues to gain momentum between 2020 and 2023, with subsequent rollouts in the United States and Europe for the treatment of osteoporosis. Designed for multiple dose, fixed dose delivery, the platform offers simplicity – a critical attribute in chronic conditions requiring frequent self-injection. Its growing adoption confirms FixPen’s role as a dependable solution for patients and pharmaceutical partners alike, particularly in therapy areas where precision and ease-of-use drive long-term adherence.

Explore the FixPen platform

The launch of SmartPilot for UnoPen transforms the widely used dial-and-dose pen into a connected injection system, reinforcing Ypsomed’s leadership in digital health. By combining proven mechanical reliability with smart sensor technology, SmartPilot enables real-time injection monitoring, adherence support, and integration into therapy management platforms. This innovation marks a major step forward in making connected care accessible at scale, especially for chronic conditions requiring regular self-injection.

Ypsomed’s YpsoMate 2.25 mL achieves a major industry first – the approval and launch of the world’s first 2.25 mL autoinjector for Teva’s Ajovy® (fremanezumab). Designed for subcutaneous delivery of large-volume biologics, this milestone confirms Ypsomed’s leadership in device innovation for complex, high-dose therapies. It also showcases the platform’s advanced capabilities in supporting chronic disease treatments where patient comfort, reliability, and usability are essential. This approval sets a new benchmark in self-injection technology and reinforces Ypsomed’s role as a preferred development partner for next-generation combination products.

Explore the YpsoMate 2.25 mL platform

Ypsomed officially inaugurates its new state-of-the-art production facility in Schwerin, Germany, significantly expanding its manufacturing footprint. The plant was designed to produce both injection systems and insulin infusion products, reinforcing the company’s industrial capacity to meet growing global demand. The Schwerin site integrates modern automation technologies and sustainable operations, contributing to improved scalability, resilience, and supply security for customers. This milestone reflects Ypsomed’s long-term commitment to operational excellence and its strategic ambition to serve the pharmaceutical market with high-quality, Swiss-engineered solutions at greater volume and global reach.

Read about the new Schwerin facility

Ypsomed's UnoPen platform marks its first launch for polycythemia vera across key European markets – expanding its application into hematologic oncology. At the same time, the company continues strengthening its leadership in insulin delivery by launching additional UnoPen-based diabetes therapies in Indonesia, China, and Russia.

These milestones underscore how Ypsomed’s platform strategy delivers practical value: enabling both large-scale insulin programs in emerging regions and niche specialty therapies in mature markets. By bridging diverse regulatory and therapeutic needs, Ypsomed proves its ability to support pharma partners of all sizes – not only with proven platforms, but with the agility and expertise required to adapt them for real-world complexity.

Ypsomed significantly expands the reach of its YpsoMate 1mL platform with five additional autoinjector launches across key markets. These include therapies for multiple sclerosis, severe asthma, sexual dysfunction and osteoporosis, demonstrating the flexibility and scalability of the YpsoMate 1 mL system across diverse therapeutic classes. The successful commercialization of these devices across Europe, North America, and Asia reinforces the platform’s reliability, rapid customization capabilities, and suitability for global deployment, helping pharma partners accelerate access to life-enhancing biologics.

In December 2019 Ypsomed officially opens new and renovated buildings at its headquarters in Burgdorf, Switzerland, marking a key step in its ongoing investment in infrastructure. The upgrades include a modernized tool manufacturing unit and expanded laboratory facilities, both essential to accelerating product development and maintaining high quality standards. These enhancements reinforce Ypsomed’s ability to innovate, prototype, and industrialize cutting-edge drug delivery solutions under one roof – ensuring greater efficiency, flexibility, and speed for customer projects. The investment underlines the company’s commitment to platform development and operational excellence, laying a strong foundation for future growth.

Read about the Burgdorf expansion

Ypsomed’s VarioJect autoinjector makes its debut with the launch of a treatment for rheumatoid arthritis (pediatric application). This marks the variable dose, single dose platform’s first entry into autoimmune diseases. With this milestone, Ypsomed further expands its platform portfolio, offering pharma partners additional flexibility to match device characteristics with specific therapeutic needs.

Explore VarioJect

FixPen becomes the first prefilled fixed-dose pen approved and launched for osteoporosis treatment. Designed to be highly intuitive and easy to handle, FixPen offers a simplified injection experience tailored to aging patient populations.

Explore the FixPen platform

Ypsomed expands the reach of its ServoPen platform with the introduction of a reusable pen for teriparatide therapy in Europe and additional global markets. This marks Ypsomed’s first reusable pen solution for osteoporosis – an area traditionally dominated by disposable devices. The launch brings new value to patients and partners through a more sustainable, lower per-injection cost delivery system. It also demonstrates the company’s ability to adapt proven technology platforms to new therapeutic areas and dosing needs, reinforcing its commitment to advancing patient self-care across a wide range of chronic conditions.

Explore the ServoPen platform

Ypsomed is among the first to introduce a prefilled, ready-to-use patch injector platform for the subcutaneous delivery of large-volume biologics – up to 10 mL. Designed for hands-free and hassle-free use, YpsoDose empowers patients to self-administer high-dose therapies at home. With integrated safety, user feedback, and connectivity features, it reflects Ypsomed’s commitment to usability-driven engineering and leadership in next-generation drug delivery.

Explore the YpsoDose platform

With multiple UnoPen and YpsoPen launches for insulin therapies in Bangladesh, China, and Russia, Ypsomed significantly strengthens its presence in high-growth diabetes markets. These launches mark a pivotal moment in expanding the company’s global footprint, with self-injection systems available in over 30 countries by 2018. This milestone reflects Ypsomed’s operational excellence, ability to scale platform technologies across diverse regulatory and healthcare environments, and its strategic focus on improving global access to high-quality diabetes care.

The launch of Mylan/Biocon’s Hulio®, a biosimilar to Humira®, marks the first commercial approval of the YpsoMate 1 mL autoinjector – a major milestone for Ypsomed’s platform strategy. It validates the scalability and global readiness of Ypsomed’s flagship device platform and underscores its role as a preferred partner for biosimilar leaders. By enabling patient-friendly delivery of high-impact biologics, this milestone reinforces Ypsomed’s commitment to platform development, operational excellence, and expanding access to innovative self-injection solutions.

Explore the YpsoMate 1 mL platform

SmartPilot for YpsoMate 1 mL marks Ypsomed’s entry into the digital health space by transforming its proven autoinjector into a connected system. The reusable SmartPilot tracks injection events, monitors adherence, and supports patients with real-time guidance and connectivity to digital ecosystems. This innovation sets a new benchmark for user-centric drug delivery and positions Ypsomed at the forefront of smart self-injection solutions for improved therapy outcomes.

Explore the SmartPilot solution

After 18 months of industrialization, Ypsomed inaugurates a state-of-the-art production line in Solothurn, Switzerland. This milestone significantly expands the company's manufacturing footprint, reinforcing its ability to scale platform technologies and meet growing global demand. The new line is designed to support high-volume, high-quality production of Ypsomed’s self-injection systems, playing a crucial role in the company’s long-term operational excellence strategy. With this investment, Ypsomed strengthens its position as a reliable and agile industrial partner for pharmaceutical companies worldwide.

Ypsomed takes a decisive step toward environmental responsibility by launching its first structured sustainability initiatives. These include dedicated energy efficiency measures across operations and the introduction of reforestation and regeneration programs to offset emissions.

This milestone marks the beginning of Ypsomed’s integrated climate strategy, embedding sustainability as a core principle across the company’s operations and product development. It lays the groundwork for future achievements such as the NetZero Program, ISCC PLUS certification, and the development of low-carbon injection systems, reaffirming Ypsomed’s commitment to environmental stewardship and responsible healthcare innovation.

UnoPen enables launches for a fertility treatment in Europe and the United States, a therapy for osteoporosis in the U.S., and an insulin product in Turkey. These launches reflect the continued global expansion of UnoPen across hormone and metabolic therapies. The platform’s adaptability to diverse drug requirements and regulatory settings underscores Ypsomed’s strength in enabling broad market access through a single device solution.

Explore the UnoPen platform

Following successful launches in diabetes therapy, Ypsomed’s ServoPen platform enters a new therapeutic area with the global launch of an apomorphine treatment for Parkinson’s disease. This marks a key diversification beyond metabolic care, proving ServoPen’s ability to support therapies with demanding, as-needed dosing. Its precision and reliability make it ideally suited for rapid symptom control in neurologic conditions. The worldwide rollout reinforces Ypsomed’s capacity to deliver robust, self-injection solutions for patients across geographies and complex disease areas.

An advanced extension of the YpsoMate platform, YpsoMate 2.25 mL Pro is specifically developed to meet the demands of next-generation biologics with high viscosity. Featuring a powerful constant-force spring and user-friendly design, it enables reliable subcutaneous injection of up to 2.25 mL without compromising ease of use. This innovation strengthens Ypsomed’s position as a partner of choice for challenging formulations in immunology, oncology, and rare disease therapies.

Ypsomed expands the reach of its reusable YpsoPen into various markets in Asia and Europe, as well as other territories around the globe. These launches reinforce Ypsomed’s role in enabling global access to high-quality insulin delivery systems and highlight the company’s operational excellence in managing multi-market rollouts. The growing adoption of YpsoPen reflects strong pharma partnerships and the flexibility of Ypsomed’s platform to support safe, effective self-injection across diverse healthcare environments.

Explore the YpsoPen platform

Ypsomed’s UnoPen platform is adopted for insulin therapy in Russia and for fertility treatments in India, underscoring its versatility across indications and geographies. These launches reinforce Ypsomed’s role as a reliable development partner for both global and regional pharma companies, and its ability to navigate diverse market dynamics. The expansion into emerging markets highlights Ypsomed’s operational excellence and strategic focus on enabling access to essential biologics through user-friendly self-injection platforms.

Explore the UnoPen platform

The introduction of YpsoMate 2.25 mL marks a major expansion of Ypsomed’s flagship autoinjector platform, enabling the subcutaneous delivery of large-volume biologics (up to 2.25 mL). Designed with a visible drug window and intuitive 2-step activation, it addresses the growing need for higher-dose therapies in immunology, oncology, and rare diseases, reinforcing Ypsomed’s leadership in scalable, patient-friendly self-injection solutions.

Explore the YpsoMate 2.25 mL platform

Ypsomed develops customized versions of its LyoTwist Trio autoinjector for GSK’s Tanzeum™/Eperzan® (albiglutide) and AstraZeneca’s Bydureon® (exenatide) – both once-weekly GLP-1 therapies for type 2 diabetes. These partnerships showcase Ypsomed’s ability to tailor device platforms to complex biologics, including dual-chamber and lyophilized formulations, reinforcing its leadership in bespoke injection systems for challenging drug delivery requirements in metabolic care.

Explore LyoTwist

UnoPen marks a major milestone in Ypsomed’s evolution into a platform-based partner. Designed as a compact, prefilled multi-dose pen, it offers an ideal balance between intuitive usability, industrial scalability, and broad therapeutic flexibility. With UnoPen, Ypsomed enables pharma companies to bring injectable therapies – from insulin to fertility and osteoporosis – to market faster across more geographies, reinforcing its role as a trusted, innovation-driven device partner.

Explore the UnoPen platform

YpsoPen marks a significant step in Ypsomed’s platform strategy – a reliable, reusable variable-dose pen with intuitive dial-and-dose handling. First launched with Dongbao for insulin therapy, it offers a cost-effective and user-friendly solution for chronic disease management, supporting partners in emerging and mature markets alike. Its modular design makes it ideal for broad customization across therapies and regions.

Explore the YpsoPen platform

With the introduction of YpsoMate 1 mL, Ypsomed redefines usability in autoinjectors through its unique 2-step, button-free design. As the industry’s first true platform autoinjector for 1 mL prefilled syringes, it enables pharma partners to accelerate time to market while improving patient confidence and safety – establishing Ypsomed as a global leader in platform-based combination product development.

Explore the YpsoMate platform

ServoPen becomes the first reusable spring-driven insulin pen awarded for design excellence. Initially launched as the Gansulin Pen in China, it was adapted for multiple markets, helping Ypsomed expand its presence in fast-growing regions. This product showcases Ypsomed’s ability to combine engineering precision with user-centered design and strengthens its reputation as a flexible development partner for pharma companies in insulin and other peptide therapies.

Explore the ServoPen platform

The Gonal-f Pen is a milestone in fertility treatment. It is the first prefilled, ready-to-use injection pen for administering FSH, revolutionizing how fertility hormones are delivered. It has a prefilled design, removing the need for cartridge changes or manual filling, minimizing patient error and improving ease of use. The pen offers fine dose increments, precise dosing, and intuitive handling, empowering patients to self-administer at home with confidence. It marks Ypsomed’s expansion beyond diabetes, showing the adaptability of our pen platforms to specialty therapies like fertility.

Following the sale of Disetronic’s insulin pump business to Roche in 2003, founder Willy Michel retains the injection systems division and establishes Ypsomed as an independent company. This strategic move lays the foundation for a focused innovation leader in self-injection devices, combining the legacy of Disetronic with a clear ambition to shape the future of drug delivery.

The OptiSet introduces a preset dosing mechanism, designed to eliminate dose dialing errors – a major step forward in patient safety and ease of use. It features clear dose indicators, simplified mechanics, and is compact and portable, aligning with growing demands for discreet and reliable diabetes care. The OptiSet becomes a benchmark product in Sanofi’s insulin portfolio, reinforcing Disetronic’s (later Ypsomed’s) reputation as a trusted device partner in diabetes treatment. The OptiSet’s engineering and patient-centered features influence future disposable pens across the industry and paves the way for modern-day combination products.

The KabiPen represents a major innovation in treating growth disorders in children and adults. It is the first injection pen designed to handle dual-chamber cartridges, which allowed reconstitution of lyophilized (freeze-dried) drugs just before injection – crucial for biologics like hGH that are unstable in solution over time. The KabiPen lays the groundwork for many future dual-chamber self-injection systems and influences the design of later biologic-compatible pens and autoinjectors. It demonstrates Disetronic’s early leadership in solving complex drug delivery challenges, especially in the biologics space, a tradition continued by Ypsomed.

OptiPen for Hoechst (Sanofi). At a time when insulin administration is mostly via syringes, the OptiPen introduces a simpler, more discreet, more user-friendly alternative, marking a breakthrough in diabetes care. It is one of the first reusable insulin pens, setting the stage for decades of pen innovation. Its design and functionality become a reference model for future insulin pen generations.

In 1984, driven by a vision to improve the lives of people with diabetes, brothers Willy (left) and Peter Michel (right) found Disetronic in Burgdorf, Switzerland – introducing the world’s first micro insulin pump and paving the way for Swiss innovation in injection and infusion systems.

Explore the history of Ypsomed